natgillin/translations-raw huggingface dataset:
Avoid soreness and skin irritation by choosing a different site from the previous one for each injection. 
Bol i nadražaj kože možete izbjeći tako što ćete za svaku injekciju odabrati drugo mjesto.
Most patients (82.0%) had undergone prior pituitary surgery, and the mean baseline mUFC was 470 nmol/24h (ULN: 166.5 nmol/24h). 
Većina bolesnika (82,0%) prethodno je imala operaciju hipofize, a srednja početna vrijednost mUFC-a bila je 470 nmol/24h (GGN: 166,5 nmol/24h).
No studies have been conducted to evaluate the absolute bioavailability of pasireotide in humans. 
Nisu provedena ispitivanja za procjenu apsolutne bioraspoloživosti pasireotida kod ljudi.
Amylase increased, prothrombin time prolonged 
Povišenje amilaze, produljeno protrombinsko vrijeme
Especially, tell your doctor if you are using: - medicines to treat irregular heartbeat, such as medicines containing disopyramide, 
Svakako recite liječniku ako uzimate: - lijekove koji liječe nepravilne otkucaje srca, kao što su lijekovi koji sadrže dizopiramid,
Pasireotide binds and activates four of the five hssts, especially hsst5, in corticotrophs of ACTH producing adenomas, resulting in inhibition of ACTH secretion. 
Pasireotid veže i aktivira četiri od pet hsst-a, osobito hsst5, u kortikotropnim adenomima koji luče ACTH, što rezultira inhibicijom izlučivanja ACTH.
Pasireotide has been shown to prolong the QT interval on the ECG in two dedicated healthy volunteer studies performed with the subcutaneous formulation. 
Dokazano je da pasireotid produžuje QT interval na EKG-u u dva posebna ispitivanja na zdravim dobrovoljcima koja su provedena sa supkutanom formulacijom.
One sterile syringe 
Jedna sterilna štrcaljka
Abdominal pain includes abdominal pain and abdominal pain upper. 
Bol u abdomenu uključuje bol u abdomenu i bol u gornjem dijelu abdomena.
Adverse reactions reported up to the cut-off date of the analysis are presented in Table 1. 
Nuspojave prijavljene do isključnog datuma za analizu navedene su u Tablici
The response in the 0.9 mg dose arm seemed to be higher for patients with lower mean UFC at baseline. 
Odgovor u kraku koji je primao dozu od 0,9 mg bio je viši za bolesnike s nižim srednjim UFC-om na početku.
The elevations were mostly asymptomatic, of low grade and reversible with continued treatment. 
Povišenja su uglavnom bila asimptomatska, niskog stupnja i reverzibilna uz nastavak liječenja.
There is a limited amount of data from the use of pasireotide in pregnant women. 
Podaci o primjeni pasireotida u trudnica su ograničeni.
Percentage of patients with: mUFC ≤ULN at Month 7 (95% CI) * mUFC ≤ULN and no prior dose increase at Month 7 (95% CI) mUFC ≤ULN or ≥50% decrease from baseline at month 7 (95% CI) Median (min, max) % mUFC change from baseline at month 7 Median (min, max) % mUFC change from baseline at month 12 * Primary endpoint using LOCF (last observation carried forward) mUFC: mean urinary free cortisol; ULN: upper limit of normal; CI: confidence interval 
Postotak bolesnika s: mUFC ≤GGN u 7. mjesecu (95% CI) * mUFC ≤GGN i bez prethodnog povećanja doze u 7. mjesecu (95% CI) mUFC ≤GGN ili smanjenje ≥50% u odnosu na početnu vrijednost u 7. mjesecu (95% CI) Medijan (min, maks)% promjene mUFC-a u odnosu na početnu vrijednost u 7. mjesecu Medijan (min, maks) % promjene mUFC-a u odnosu na početnu vrijednost u 12. mjesecu * Mjera primarnog ishoda koristeći LOCF (eng. last observation carried forward) mUFC: srednji slobodni kortizol u urinu; GGN: gornja granica normale; CI: interval pouzdanosti
A few cases of concurrent elevations in ALT greater than 3 x ULN and bilirubin greater than 2 x ULN have been observed with the subcutaneous formulation, however not in patients treated with pasireotide intramuscular use. 
Bilo je opaženo nekoliko slučajeva istodobnih povišenja ALT-a većih od 3 x GGN i bilirubina većih od 2 x GGN uz supkutanu formulaciju, ali ne u bolesnika liječenih pasireotidom intramuskularno.
(ciclosporin); - medicines to treat blood sugar levels that are too high (as in diabetes) or too low 
(ciklosporin), - lijekove koji se koriste za liječenje razina šećera u krvi koje su previsoke (kao kod šećerne bolesti) ili preniske (hipoglikemija), kao što su:
Within each frequency grouping, adverse reactions are presented in the order of decreasing seriousness. 
Unutar svake grupe učestalosti, nuspojave su prikazane u padajućem nizu prema ozbiljnosti.
The safety profile of Signifor was consistent with the somatostatin analogue class, except for the occurrence of hypocortisolism and degree of hyperglycaemia. 
Sigurnosni profil Signifora bio je dosljedan sa skupinom analoga somatostatina, osim kad je riječ o pojavi hipokortizolizma i stupnju hiperglikemije.
Pasireotide is metabolically highly stable and in vitro data show that pasireotide is not a substrate, inhibitor or inducer of CYP450. 
Pasireotid je metabolički visoko stabilan, a in vitro podaci pokazuju da pasireotid nije supstrat, inhibitor ili induktor CYP450.
In acromegaly patients elevated fasting glucose level was the most frequently reported grade 3/4 laboratory abnormality in the two phase III studies. 
U bolesnika s akromegalijom povišena razina glukoze natašte bila je najčešće prijavljena laboratorijska abnormalnost stupnja 3/4 u dva ispitivanja faze III.
The recommended initial dose for patients with moderate hepatic impairment (Child Pugh B) is 0.3 mg twice a day (see section 5.2). 
Preporučena početna doza za bolesnike s umjerenim oštećenjem jetre (Child Pugh B) iznosi 0,3 mg dvaput na dan (vidjeti dio 5.2).
In healthy volunteers, pasireotide intramuscular use is widely distributed with large apparent volume of distribution (Vz/F >100 litres). 
U zdravih dobrovoljaca pasireotid primijenjen intramuskularno ima opsežnu distribuciju uz veliki volumen distribucije (Vz/F >100 litara).
Based on in vitro data pasireotide is not a substrate of the efflux transporter BCRP (breast cancer resistance protein) nor of the influx transporters OCT1 (organic cation transporter 1), OATP (organic anion-transporting polypeptide) 1B1, 1B3 or 2B1. 
Na temelju in vitro podataka pasireotid nije supstrat BCRP transportera za izbacivanje (engl. breast cancer resistance protein - protein rezistencije raka dojke) niti transportera za ubacivanje OCT1 (engl. organic cation transporter 1 - transporter organskih kationa 1), OATP (engl. organic anion-transporting polypeptide - polipeptid koji transportira organske anione ) 1B1, 1B3 ili 2B1.
- Abnormal blood test results (sign of high level of creatine phosphokinase, glycosylated haemoglobin, lipase in the blood) - Hair loss 
- Poremećeni rezultati krvnih pretraga (znak visoke razine kreatin fosfokinaze, glikiranog hemoglobina, lipaze u krvi) - Gubitak kose
All cases of concurrent elevations were identified within ten days of initiation of treatment with Signifor. 
Svi slučajevi istodobnih povišenja bili su utvrđeni u roku od deset dana od početka liječenja Signiforom.
Dose reductions or discontinuation of treatment with pasireotide due to hyperglycaemia were infrequent in clinical studies with pasireotide. 
Smanjenja doze ili prekidi terapije pasireotidom zbog hiperglikemije nisu bili učestali u kliničkim ispitivanjima s pasireotidom.
Prepare the injection site with an alcohol wipe. 
Pripremite mjesto primjene injekcije alkoholnom maramicom.
Additionally, tolerability and repeated dose toxicity studies were conducted with pasireotide via the intramuscular route. 
Uz to, ispitivanja podnošljivosti i toksičnosti ponovljenih doza provedena su s pasireotidom primijenjenim intramuskularno.
Management of suspected adverse reactions or over-response to treatment (IGF-1 < lower limit of normal) may require temporary dose reduction of Signifor. 
Zbrinjavanje u slučaju sumnje na nuspojave ili prekomjernog odgovora na liječenje (IGF-1 < donje granice normale) moglo bi zahtijevati privremeno smanjenje doze Signifora.
The percentage of patients achieving biochemical control, including those patients with IGF-1 <LLN was 25.9% in the pasireotide intramuscular use group and 0% in the octreotide intramuscular use group. 
Postotak bolesnika koji su postigli biokemijsku kontrolu, uključujući one bolesnike s IGF-1 <DGN bio je 25,9% u skupini koja je primala pasireotid intramuskularno i 0% u skupini koja je primala oktreotid intramuskularno.
In the pivotal study with patients who did not receive prior medical treatment, the proportion of patients who required commencement of anti-diabetic therapy during the study was 36% in the Signifor arm compared to 4.4% in the active control arm. 
U ključnom ispitivanju s bolesnicima koji prethodno nisu primali terapiju lijekovima, udio bolesnika u kojih je bilo potrebno započeti terapiju antidijabetikom tijekom ispitivanja bio je 36% u skupini koja je primala Signifor u usporedbi s 4,4% u skupini s aktivnom kontrolom.
Common Toxicity Criteria (CTC) Grade 3 and 4 adverse reactions were mostly related to hyperglycaemia. 
Nuspojave stupnja 3 i 4 prema Zajedničkim kriterijima toksičnosti (CTC) bile su uglavnom povezane s hiperglikemijom.
Remove the packaging from the vial adapter by lifting it straight up as shown. 
Uklonite pakiranje s nastavka za bočicu podizanjem prema gore kako je prikazano.
Decreases were also demonstrated by the overall percentage of change in mean and median UFC levels at month 6 and 12 as compared to baseline values (see Table 3). 
Smanjenja su bila dokazana i ukupnim postotkom promjene u srednjoj vrijednosti i medijanu razina UFC-a u 6. i 12. mjesecu u usporedbi s početnim vrijednostima (vidjeti Tablicu 3).
Decreased total body clearance and increased pharmacokinetic exposures have been seen with increasing age. 
Kod starije dobi uočeni su smanjeni ukupni tjelesni klirens i povećana farmakokinetička izloženost.
Treatment of adult patients with acromegaly for whom surgery is not an option or has not been curative and who are inadequately controlled on treatment with another somatostatin analogue. 
Liječenje odraslih bolesnika s akromegalijom kod kojih kirurški zahvat nije moguć ili nije postigao izlječenje te koji nisu odgovarajuće kontrolirani terapijom s drugim analogom somatostatina.
Multipacks (40 mg and 60 mg strengths only): each multipack contains 3 intermediate cartons, each containing a blister tray with one injection kit (one vial and, in a separate sealed section, one pre-filled syringe, one vial adapter and one safety engineered needle for injection). 
Višestruka pakiranja (samo jačine od 40 mg i 60 mg): svako višestruko pakiranje sadrži 3 međupakiranja, od kojih svako sadrži podložak s jednim setom za primjenu injekcije (jedna bočica te, u odvojenom zatvorenom dijelu, jedna napunjena štrcaljka, jedan nastavak za bočicu i jedna igla za injekciju sa zaštitnim mehanizmom).
Gently tap the syringe to remove any visible bubbles and expel them from the syringe. 
Lagano kucnite po štrcaljki da uklonite vidljive mjehuriće ako ih ima i izbacite ih iz štrcaljke.
Therapy with pasireotide should be discontinued if the patient develops jaundice or other signs suggestive of clinically significant liver dysfunction, in the event of a sustained increase in AST (aspartate aminotransferase) or ALT of 5 x ULN or greater, or if ALT or AST elevations greater than 3 x ULN occur concurrently with bilirubin elevations greater than 2 x ULN. 
Terapiju pasireotidom treba prekinuti ako bolesnik razvije žuticu ili druge znakove koji upućuju na klinički značajnu disfunkciju jetre, u slučaju održanog povišenja AST-a (aspartat aminotransferaze) ili ALT-a od 5 x GGN ili većeg, ili ako se povišenja ALT-a ili AST-a veća od 3 x GGN pojave istodobno s povišenjima bilirubina većima od 2 x GGN.
Nearly half of the patients had additional prior medical treatment for acromegaly other than somatostatin analogues. 
Gotovo polovica bolesnika prethodno je primala terapiju lijekovima za akromegaliju koja nije uključivala analoge somatostatina.
The recommended initial dose is 0.6 mg pasireotide by subcutaneous injection twice a day. 
Preporučena početna doza je 0,6 mg pasireotida supkutanom injekcijom dvaput na dan.
DO NOT USE if the medicine has expired or if the dose is incorrect. 
Lijek NE KORISTITE ako mu je istekao rok valjanosti ili ako doza nije odgovarajuća.
The patients recovered without clinical sequelae and liver function test results returned to baseline values after discontinuation of treatment. 
Bolesnici su se oporavili bez kliničkih posljedica, a rezultati testova jetrene funkcije vratili su se na početne vrijednosti nakon prekida liječenja.
Grade 3 adverse reactions were observed in 35.8% of patients and Grade 4 adverse reactions in 2.5% of patients. 
Nuspojave 3. stupnja bile su uočene kod 35,8% bolesnika, a nuspojave 4. stupnja kod 2,5% bolesnika.
In medically naïve patients (study C2305), the mean absolute increase in FPG and HbA1c was similar at most of the time points for all patients treated with pasireotide intramuscular use irrespective of baseline values. 
U bolesnika bez prethodne terapije lijekovima (ispitivanje C2305), srednje apsolutno povećanje FPG-a i HbA1c bilo je slično u većini vremenskih točaka za sve bolesnike liječene pasireotidom primijenjenim intramuskularno bez obzira na početne vrijednosti.
• metformin, liraglutide, vildagliptin, nateglinide (antidiabetic medicines). 
• metformin, liraglutid, vildagliptin, nateglinid (antidijabetici).
Bradycardia has been reported with the use of pasireotide (see section 4.8). 
Kod primjene pasireotida prijavljivana je bradikardija (vidjeti dio 4.8).
Careful monitoring is recommended in patients with cardiac disease and/or risk factors for bradycardia, such as history of clinically significant bradycardia or acute myocardial infarction, high-grade heart block, congestive heart failure (NYHA Class III or IV), unstable angina, sustained ventricular tachycardia, ventricular fibrillation. 
Preporučuje se pažljivo praćenje kod bolesnika sa srčanom bolešću i/ili rizičnim čimbenicima za bradikardiju, kao što su klinički značajna bradikardija ili akutni infarkt miokarda u anamnezi, blok srca visokog stupnja, kongestivno zatajenje srca (NYHA klasa III ili IV), nestabilna angina, postojana ventrikularna tahikardija, ventrikularna fibrilacija.
If a dose of Signifor is missed, the next injection should be administered at the scheduled time. 
Ako se propusti doza Signifora, sljedeću injekciju treba primijeniti u predviđeno vrijeme.
The proportion of patients with a reduction of tumour volume greater than 20% at month 12 was 80.8% for pasireotide intramuscular use and 77.4% for octreotide intramuscular use. 
Udio bolesnika sa smanjenjem volumena tumora većim od 20% u 12. mjesecu bio je 80,8% za pasireotid primijenjen intramuskularno te 77,4% za oktreotid primijenjen intramuskularno.
Patients were randomised in a 1:1 ratio to one of two treatment groups in each of the following two strata: 1) patients who had undergone one or more pituitary surgeries but had not been treated medically or 2) de novo patients presenting a visible pituitary adenoma on MRI who had refused pituitary surgery or for whom pituitary surgery was contraindicated. 
Bolesnici su bili randomizirani u omjeru 1:1 u jednu od dvije terapijske skupine u svakoj od sljedeće dvije kategorije: 1) bolesnici koji su imali jednu ili više operacija hipofize, ali nisu primali terapiju lijekovima ili 2) de novo bolesnici s vidljivim adenomom hipofize na MRI-ju koji su odbili operaciju hipofize ili za koje je operacija hipofize bila kontraindicirana.
The phase III clinical studies in acromegaly patients did not identify any clinically meaningful differences in the QT prolongation events between pasireotide intramuscular use and the somatostatin analogues which were tested as active comparator. 
U kliničkim ispitivanjima faze III u bolesnika s akromegalijom nisu utvrđene nikakve klinički značajne razlike u događajima produženja QT intervala između pasireotida primijenjenog intramuskularno i analoga somatostatina koji su bili ispitivani kao aktivni komparator.
Signifor may have a minor effect on the ability to drive and use machines, because some of the side effects you may experience while using Signifor, such as headache, dizziness and tiredness, may reduce your ability to drive and use machines safely. 
Signifor može imati mali utjecaj na sposobnost upravljanja vozilima i rada sa strojevima zato što neke od nuspojava koje možete osjetiti dok primjenjujete Signifor, kao što su omaglica, glavobolja i umor, mogu smanjiti Vašu sposobnost da sigurno upravljate vozilima i strojevima.
No QTcF values >500 ms were observed in any of the pivotal studies. 
Ni u jednom od ključnih ispitivanja nije bila opažena vrijednost QTcF-a >500 ms.
The primary efficacy endpoint was met; the percentage of patients achieving biochemical control was 31.3% and 19.2% for pasireotide intramuscular use and octreotide intramuscular use, respectively, demonstrating a statistically significant superior result favouring pasireotide intramuscular use (p-value = 0.007) (Table 4). 
Mjera primarnog ishoda djelotvornosti bila je ispunjena; postotak bolesnika koji su postigli biokemijsku kontrolu bio je 31,3% za pasireotid primijenjen intramuskularno te 19,2% za oktreotid primijenjen intramuskularno, što je pokazalo statistički značajan superioran rezultat u korist pasireotida primijenjenog intramuskularno (p-vrijednost = 0,007) (Tablica 4).
Anticipated pharmacokinetic interactions resulting in effects on pasireotide 
Očekivane farmakokinetičke interakcije koje utječu na pasireotid
The study enrolled 162 patients with a baseline UFC >1.5 x ULN who were randomised in a 1:1 ratio to receive a subcutaneous dose of either 0.6 mg or 0.9 mg Signifor twice daily. 
Ispitivanje je uključivalo 162 bolesnika s početnim UFC-om >1,5 x GGN koji su bili randomizirani u omjeru 1:1 na primjenu supkutane doze od 0,6 mg ili 0,9 mg Signifora dvaput na dan.
Patients were randomised in a 1:1 ratio to receive starting doses of either 10 mg or 30 mg pasireotide, with a possibility to up-titrate to a maximum dose of 40 mg every 28 days. 
Bolesnici su bili randomizirani u omjeru 1:1 na primanje početnih doza pasireotida od 10 mg ili 30 mg, uz mogućnost postupnog povećanja do maksimalne doze od 40 mg svakih 28 dana.
Monitoring for an effect on the QTc interval is advisable 21 days after the beginning of the treatment and as clinically indicated thereafter. 
Savjetuje se praćenje učinka na QTc interval 21 dan nakon početka terapije te nakon toga u skladu s kliničkim indikacijama.
Fasting plasma glucose and HbA1c values generally decreased over the 28 days following pasireotide discontinuation but remained above baseline values. 
Vrijednosti glukoze u plazmi natašte i HbA1c općenito su se smanjile tijekom 28 dana nakon prekida uzimanja pasireotida, ali ostala su iznad početnih vrijednosti.
Your doctor or nurse will inject Signifor. 
Vaš liječnik ili medicinska sestra dat će Vam injekciju Signifora.
60 ampoules (10x6) 
60 ampula (10x6)
If you accidentally use more Signifor than your doctor prescribed, immediately contact your doctor, nurse or pharmacist. 
Ako slučajno primijenite više Signifora nego što Vam je liječnik propisao, odmah se obratite liječniku, medicinskoj sestri ili ljekarniku.
Powder: slightly yellowish to yellowish powder. 
Prašak: blago žućkasti do žućkasti prašak.
Signifor solution for injection should be free of visible particles, clear and colourless. 
Signifor otopina za injekciju treba biti bez vidljivih čestica, bistra i bezbojna.
Turn syringe and vial upside down, slowly pull the plunger back and draw the entire content from the vial into the syringe. 
Preokrenite naopako štrcaljku i bočicu, polako povucite klip unatrag i izvucite cjelokupni sadržaj iz bočice u štrcaljku.
One Signifor ampoule 
Jedna ampula Signifora
FPG and HbA1c increases were dose-dependent, and values generally decreased following pasireotide intramuscular use discontinuation but remained above baseline values. 
Povećanja FPG-a i HbA1c bila su ovisna o dozi, a vrijednosti su se općenito smanjile nakon obustave primjene intramuskularnog pasireotida, ali su ostale iznad početnih vrijednosti.
Decreases were also demonstrated by the overall percentage change from baseline in mean and median mUFC levels at month 7 and 12. 
Smanjenja su bila dokazana i ukupnim postotkom promjene od početnih vrijednosti u srednjim vrijednostima i medijanima mUFC-a u 7. i 12. mjesecu.
Signifor should only be administered by a trained healthcare professional. 
Signifor smije primjenjivati samo educirani zdravstveni radnik.
Signifor is a medicine that contains the active substance pasireotide. 
Signifor je lijek koji sadrži djelatnu tvar pasireotid.
Remove the plastic cap from the vial and clean the rubber stopper of the vial with an alcohol wipe. 
Uklonite plastični zatvarač s bočice i očistite gumeni čep bočice alkoholnom maramicom.
The maximum recommended dose for these patients is 0.6 mg twice a day. 
Najveća preporučena doza za te bolesnike je 0,6 mg dvaput na dan.
If you have liver disease before you start Signifor treatment, your doctor may want to start your treatment with a dose of one ampoule of Signifor 0.3 mg twice a day. 
Ako imate bolest jetre prije nego što započnete liječenje Signiforom, liječnik će možda htjeti da započnete liječenje dozom od jedne ampule Signifora 0,3 mg dvaput na dan.
Bradycardic medicinal products 
Lijekovi protiv bradikardije
Twelve months after crossover, the percentage of patients achieving biochemical control was 17.3% (14/81) for pasireotide intramuscular use and 0% (0/38) for octreotide intramuscular use. 
Dvanaest mjeseci nakon ukrižene zamjene, postotak bolesnika koji su postigli biokemijsku kontrolu bio je 17,3% (14/81) za pasireotid primijenjen intramuskularno te 0% (0/38) za oktreotid primijenjen intramuskularno.
Hold the base of the ampoule in one hand. 
Primite tijelo ampule jednom rukom.
Signifor is available in packs containing 6 ampoules or in multipacks containing 18 (3 packs of 6), 30 (5 packs of 6) or 60 (10 packs of 6) ampoules. 
Signifor je dostupan u pakiranjima koja sadrže 6 ampula ili u višestrukim pakiranjima koja sadrže 18 (3 pakiranja po 6), 30 (5 pakiranja po 6) ili 60 (10 pakiranja po 6) ampula.
Episodes of torsade de pointes were not observed either in those studies or in clinical studies in other patient populations. 
Epizode torsade de pointes nisu bile uočene ni u jednom od tih ispitivanja ili kliničkih ispitivanja s drugim populacijama bolesnika.
The proportion of patients who either attained mUFC ≤ULN or a mUFC reduction from baseline of at least 50% was 50.0% in the 10 mg dose group and 56.6% in the 30 mg dose groups (Table 5). 
Udio bolesnika koji su ili postigli mUFC ≤GGN ili smanjenje mUFC-a u odnosu na početnu vrijednost od najmanje 50% bio je 50,0% u skupini koja je primala 10 mg, te 56,6% u skupini koja je primala 30 mg (Tablica 5).
18 ampoules (3x6) 
18 ampula (3x6)
Somatostatin receptors are expressed in many tissues, especially in neuroendocrine tumours in which hormones are excessively secreted, including ACTH in Cushing's disease. 
Somatostatinski receptori izraženi su u mnogim tkivima, osobito u neuroendokrinim tumorima u kojima se prekomjerno izlučuju hormoni, uključujući ACTH u Cushingovoj bolesti.
Decreases in systolic and diastolic blood pressure and in body weight were observed in both dose groups at month 7. 
Smanjenja u sistoličkom i dijastoličkom krvnom tlaku i tjelesnoj težini bila su uočena u 7. mjesecu u obje dozne skupine.
For instructions on reconstitution of the medicinal product before administration, see section 6.6. 
Za uputu o razrjeđivanju lijeka prije primjene, vidjeti dio 6.6.
The primary efficacy endpoint was the proportion of patients with a reduction of mean GH level to <2.5 μg/l and the normalisation of IGF-1 to within normal limits (age and sex related) at month 12. 
Mjera primarnog ishoda djelotvornosti bila je udio bolesnika sa smanjenjem srednje razine GH-a na <2,5 μg/l te normalizacijom IGF-1 do unutar normalnih granica (povezano s dobi i spolom) u 12. mjesecu.
Treatment with Signifor leads to rapid suppression of ACTH (adrenocorticotropic hormone) secretion in Cushing's disease patients. 
Liječenje Signiforom vodi do brze supresije izlučivanja ACTH-a (adrenokortikotropnog hormona) u bolesnika s Cushingovom bolešću.
1 vial of powder 
1 bočica praška